Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by First Bank & Trust

First Bank & Trust raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,269 shares of the biopharmaceutical company’s stock after buying an additional 2,569 shares during the quarter. First Bank & Trust’s holdings in Gilead Sciences were worth $2,803,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Capital World Investors boosted its stake in Gilead Sciences by 2.0% in the 4th quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock worth $6,753,350,000 after purchasing an additional 1,642,736 shares during the period. Capital Research Global Investors boosted its position in shares of Gilead Sciences by 3.0% in the fourth quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock worth $4,832,824,000 after buying an additional 1,743,418 shares during the period. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after buying an additional 2,350,550 shares in the last quarter. Morgan Stanley raised its position in Gilead Sciences by 0.9% during the third quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after buying an additional 158,794 shares during the period. Finally, Norges Bank purchased a new stake in Gilead Sciences in the 4th quarter worth about $1,301,624,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $0.22 during trading hours on Friday, hitting $68.61. 9,590,049 shares of the company traded hands, compared to its average volume of 9,497,302. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The firm has a 50-day moving average of $65.98 and a 200 day moving average of $72.58. The stock has a market capitalization of $85.48 billion, a price-to-earnings ratio of 190.58, a P/E/G ratio of 2.93 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the prior year, the business earned $1.37 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.49%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is presently 855.56%.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Maxim Group cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday, April 24th. Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Finally, Barclays reduced their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $83.47.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.